Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism ; volume:14 ; number:1 ; day:4 ; month:4 ; year:2014 ; pages:1-7 ; date:12.2014
BMC cancer ; 14, Heft 1 (4.4.2014), 1-7, 12.2014
- Urheber
-
Schoellhammer, Hans F.
- Beteiligte Personen und Organisationen
-
Hsu, Felicia
Vito, Courtney
Chu, Peiguo
Park, Jinha
Waisman, James
Kim, Joseph
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-242
- URN
-
urn:nbn:de:1111-2016030418414
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schoellhammer, Hans F.
- Hsu, Felicia
- Vito, Courtney
- Chu, Peiguo
- Park, Jinha
- Waisman, James
- Kim, Joseph
- SpringerLink (Online service)
Ähnliche Objekte (12)
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer